Patents by Inventor Shixin Qin
Shixin Qin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240061317Abstract: This application provides a camera module and an electronic device, and relates to the field of electronic device technologies. The camera module includes an optical camera lens, a variable aperture, and an SMA motor. The variable aperture has an aperture hole whose size is adjustable. The SMA motor includes a first carrier, a base, and an SMA drive assembly. The optical camera lens is fastened to the first carrier. The SMA drive assembly is connected between the first carrier and the base. The SMA drive assembly is configured to drive the first carrier, the optical camera lens, and the variable aperture to move together relative to the base, so as to implement automatic focusing and/or optical image stabilization.Type: ApplicationFiled: December 13, 2021Publication date: February 22, 2024Inventors: Zhongcheng You, Dengfeng Li, Haibo Wan, Gang Wang, Shixin Qin, Xiaohan Liu
-
Patent number: 10941211Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: July 6, 2018Date of Patent: March 9, 2021Assignees: MILLENNIUM PHARMACEUTICALS, INC., AMGEN BRITISH COLUMBIA INC.Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Publication number: 20180355062Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: July 6, 2018Publication date: December 13, 2018Applicants: Millennium Pharmaceuticals, Inc., Amgen British Columbia Inc.Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Publication number: 20170081413Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: ApplicationFiled: May 4, 2016Publication date: March 23, 2017Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Publication number: 20160009808Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: ApplicationFiled: September 23, 2015Publication date: January 14, 2016Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Patent number: 9163084Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: GrantFiled: June 28, 2011Date of Patent: October 20, 2015Assignee: Millennium Pharmaceuticals, Inc.Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Publication number: 20140322233Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: June 2, 2014Publication date: October 30, 2014Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Patent number: 8846047Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: GrantFiled: October 4, 2010Date of Patent: September 30, 2014Assignee: The Feinstein Institute for Medical ResearchInventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Patent number: 8785600Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: October 22, 2010Date of Patent: July 22, 2014Assignees: Millennium Pharmaceuticals, Inc., Amgen British ColumbiaInventors: Samuel S. Nam, Edward A. Greenfield, Theresa L. O'Keefe, Shixin Qin, John Babcook
-
Patent number: 8129130Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: GrantFiled: March 18, 2011Date of Patent: March 6, 2012Assignees: The Feinstein Institute for Medical Research, MedImmune, LLCInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Publication number: 20110287023Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: March 18, 2011Publication date: November 24, 2011Applicants: Critical Therapeutics, Inc., MedImmune, LLCInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Publication number: 20110280875Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: ApplicationFiled: June 28, 2011Publication date: November 17, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Publication number: 20110217292Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: ApplicationFiled: October 4, 2010Publication date: September 8, 2011Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Patent number: 7994287Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: GrantFiled: June 23, 2008Date of Patent: August 9, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Publication number: 20110110936Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: October 22, 2010Publication date: May 12, 2011Inventors: Samuel S. Nam, Edward A. Greenfield, Theresa L. O'Keefe, Shixin Qin, John Babcook
-
Patent number: 7858326Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: GrantFiled: August 1, 2008Date of Patent: December 28, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Publication number: 20100061983Abstract: The present invention relates to proteins or polypeptides, referred to herein as isolated and/Or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.Type: ApplicationFiled: September 21, 2007Publication date: March 11, 2010Applicants: Millennium Pharmaceuticals, Inc., Theodor-Kocher InstituteInventors: Marcel Loetscher, Bernhard Moser, Shixin Qin, Charles R. Mackay
-
Patent number: 7632500Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: GrantFiled: September 20, 2007Date of Patent: December 15, 2009Assignee: Cornerstone Therapeutics, Inc.Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Publication number: 20090285835Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: ApplicationFiled: June 23, 2008Publication date: November 19, 2009Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Publication number: 20090202542Abstract: The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.Type: ApplicationFiled: November 19, 2008Publication date: August 13, 2009Applicant: Critical Therapeutics, Inc.Inventors: Theresa O'Keefe, Peter Luciano, Shixin Qin